May 27, 2018 8:23 PM ET


Company Overview of IDT Biologika GmbH

Company Overview

IDT Biologika GmbH develops, manufactures, and markets animal health products, human vaccines, and pharmaceuticals. Its animal health products include vaccines and pharmaceuticals for farm and companion animals; natural hormone preparations for pig production; cell-cultivated vaccines against influenza; vaccines against salmonella typhimurium and s. choleraesuis; vaccines for pigs; live salmonella vaccine against s. typhimurium and s. enteriditis for use in chickens; and vaccines for combating zoonoses. The company also provides development services for vaccines ranging from clinical phase I to III; and commercial supplies for viral and bacterial human vaccines. Its pharmaceuticals comprise ...

Am Pharmapark

Dessau-Roßlau,  06861


Founded in 1921


49 34901 8850


49 34901 885 5323

Key Executives for IDT Biologika GmbH

Chief Executive Officer and Managing Director
Head of Quality Control
Managing Director and Head of Global Animal Health Division
Compensation as of Fiscal Year 2017.

IDT Biologika GmbH Key Developments

IDT Biologika Acquires Facility in Canada to Expand Investment in the Americas

IDT Biologika purchased a new facility in Canada that will significantly enhance the company's vaccine development and manufacturing capabilities. The companies plan to build out the facility as a technological beacon for veterinary medicine and livestock health in the region. The new IDT Biologika building in Cambridge will be home to a animal vaccine manufacturing hub serving North America. The nearly 32,000-square foot facility will support a significant increase in IDT's production capacity and innovative and efficient processes for the commercial production of animal health vaccines, including antigen production, blending-filling-packaging, storage, a clean room lab, offices and meeting areas, and bacterial research that meet high quality requirements. Automation as well as cutting-edge equipment and computing capabilities are considered in construction and installation plans.

IDT Biologika Establishes Animal Health Americas Business Unit; Appoints José Ochoa as Head of IDT Biologika Animal Health Americas

IDT Biologika announced that it has established a new organization to serve the animal health needs of veterinarians, farmers and government agencies in the Americas. IDT Animal Health Americas will leverage the company’s global expertise and technology to offer an innovative range of high-quality autogenous, wildlife and commercial vaccines and diagnostic solutions for use in animals. José Ochoa has been appointed head of the newly formed business unit, IDT Biologika Animal Health Americas. José Ochoa, who joined IDT from Emergent BioSolutions in 2015, has been appointed head of the new regional business unit for the Americas, responsible for overall growth and operations. He takes on this new role within Animal Health while maintaining his position as Chief Business Officer with IDT Biologika Corporation in Rockville, Maryland. Jackie Gallant, Founder and President of Gallant Custom Laboratories, sits on IDT’s Scientific Advisory Board and will continue to oversee research and development of innovative autogenous biologics, with a focus on serving animal health customers throughout Canada. She will be supported by Dr. Guy Moser, General Manager, Gallant Custom Laboratories, and Sam Mostafa, Gallant Custom Laboratories, who will serve as key account manager for animal health vaccines in Canada.

IDT Biologika Wins Contract for Live Virus Filling and Finishing Services from BARDA

IDT Biologika announced that the Biomedical Advanced Research and Development Authority (BARDA) within the office of the Assistant for Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS) has awarded the company an Indefinite Quantity, Indefinite Delivery (IDIQ) contract1 to provide live virus filling and finishing services with an initial commitment of $100,000, subject to task order(s) for a maximum amount of $50 million. BARDA seeks to establish fill/finish capabilities for use of live-vectored virus products in clinical development through licensure. BARDA has contracted with IDT Biologika to provide services to support cGMP and non-GMP filling and finishing of a variety of medical countermeasure products. The company will initially provide services to support live virus/vectored vaccine fill finish and potentially for small molecule injectables, large molecule sterile injectables, monoclonal antibodies and other development-stage and FDA-approved medical countermeasures. The BARDA contract may be performed over a five-year period and addresses two types of requirements: the first being fill finish services to support the development of live/vectored virus product candidates and medical countermeasures. The second provides for rapid response readiness for fill finish services for medical countermeasures within an accelerated time frame.

Similar Private Companies By Industry

Company Name Region
3B Pharmaceuticals GmbH Europe
Accelsiors Group International Europe
advanceCor GmbH Europe
Aenova Group GmbH Europe
Aenova Holding GmbH Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact IDT Biologika GmbH, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at